Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery

doi:10.1016/j.soard.2022.07.002

Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.

Original language	English (US)
Pages (from-to)	1109-1119
Number of pages	11
Journal	Surgery for Obesity and Related Diseases
Volume	18
Issue number	9
DOIs	https://doi.org/10.1016/j.soard.2022.07.002
State	Published - Sep 2022

Keywords

Bariatric Surgery/adverse effects
Humans
United States

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.soard.2022.07.002

Cite this

Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery (2022). Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surgery for Obesity and Related Diseases, 18(9), 1109-1119. https://doi.org/10.1016/j.soard.2022.07.002

Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. / Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery.
In: Surgery for Obesity and Related Diseases, Vol. 18, No. 9, 09.2022, p. 1109-1119.

Research output: Contribution to journal › Review article › peer-review

Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery 2022, 'Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee', Surgery for Obesity and Related Diseases, vol. 18, no. 9, pp. 1109-1119. https://doi.org/10.1016/j.soard.2022.07.002

@article{b8b8e4c154884941af40c9b3587bda16,

title = "Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee",

abstract = "The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.",

keywords = "Bariatric Surgery/adverse effects, Humans, United States",

author = "{Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery} and Vosburg, {R. Wesley} and {El Chaar}, Maher and {El Djouzi}, Sofiane and Salvatore Docimo and Danbi Choi and Teresa LaMasters and Gitanjali Srivastava and Shukla, {Alpana P.} and Oviedo, {Rodolfo J.} and Angela Fitch and Azagury, {Dan Elison}",

note = "Funding Information: We thank Holly Loftus for her assistance in reviewing this paper. Publisher Copyright: {\textcopyright} 2022 American Society for Metabolic and Bariatric Surgery",

year = "2022",

month = sep,

doi = "10.1016/j.soard.2022.07.002",

language = "English (US)",

volume = "18",

pages = "1109--1119",

journal = "Surgery for Obesity and Related Diseases",

issn = "1550-7289",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

AU - Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery

AU - Vosburg, R. Wesley

AU - El Chaar, Maher

AU - El Djouzi, Sofiane

AU - Docimo, Salvatore

AU - Choi, Danbi

AU - LaMasters, Teresa

AU - Srivastava, Gitanjali

AU - Shukla, Alpana P.

AU - Oviedo, Rodolfo J.

AU - Fitch, Angela

AU - Azagury, Dan Elison

PY - 2022/9

Y1 - 2022/9

N2 - The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.

AB - The following literature search is in response to inquiries made to the American Society for Metabolic and Bariatric Surgery (ASMBS) regarding antiobesity medication (AOM) use in patients who are having or have already had metabolic and bariatric surgery (MBS). These recommendations are based on current clinical knowledge, expert opinion, and published peer-reviewed scientific evidence available at this time. This paper is not intended to establish a local, regional, or national standard of care. The paper will be revised in the future as additional evidence becomes available.

KW - Bariatric Surgery/adverse effects

KW - Humans

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85136526326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136526326&partnerID=8YFLogxK

U2 - 10.1016/j.soard.2022.07.002

DO - 10.1016/j.soard.2022.07.002

M3 - Review article

C2 - 36028428

AN - SCOPUS:85136526326

SN - 1550-7289

VL - 18

SP - 1109

EP - 1119

JO - Surgery for Obesity and Related Diseases

JF - Surgery for Obesity and Related Diseases

IS - 9

ER -

Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this